The COMPASS trial for the first time has shown that dual pathway inhibition with low-dose rivaroxaban and aspirin has a favorable benefit risk profile in patients with polyvascular disease like CAD, PAD and cerebrovascular disease.

Since benefit is seen more in <65-year population than >65-year population, Indian patients who are younger will benefit more from the dual pathway inhibition therapy.